Compound capable of modulating interaction between the PTB1 domain of FE65 protein and hnRNPL and/or FEBP1 protein, useful to treat neurological disorders including Alzheimer's disease

摘要

A compound capable of at least partially modulating interactions between hnRNPL (undefined) and/or FEBP1 (undefined) proteins or their homologues and the PTB1 domain of FE65, is new. Independent claims are also included for the following: (i) a 337 amino acid sequence (I) fully defined in the specification or its derivative or fragment; (ii) a polypeptide (II) derived from a 349 amino acid sequence fully defined in the specification having a non-functional effector region; (iii) a nucleic acid encoding the above polypeptides; (iv) a nucleic acid capable of hybridizing with the above nucleic acid or its complement; (v) a vector comprising one of the above nucleic acids; (vi) a disarmed recombinant virus comprising one of the above nucleic acids; (vii) an antibody or its fragment directed against the above polypeptide; (viii) a non-peptide or naturally not exclusively peptide compound susceptible for modulating interaction between hnRNPL and/or FEBP1 proteins or their homologues and the PTB1 domain of FE65; (ix) selecting or characterizing active molecules, comprising selecting for molecules capable of binding to sequence I or II or their fragments; and (x) producing the above peptide compound, comprising culturing a cell containing the above nucleic acid or vector under expression conditions, and recovering the peptide compound product. ACTIVITY : Nootropic; neuroprotective. No supporting data is given. MECHANISM OF ACTION : Modulating protein-protein interactions, particularly to prevent formation of amyloid plaques.